Efficacy and advantages in the use of low doses of anandron and estrogen combination in the treatment of prostate cancer

@article{Rao1988EfficacyAA,
  title={Efficacy and advantages in the use of low doses of anandron and estrogen combination in the treatment of prostate cancer},
  author={B. Ramanath Rao and Albert A. Geldof and Clasina L. van der Wilt and Herman J. de Voogt},
  journal={The Prostate},
  year={1988},
  volume={13}
}
Treatment effects of RU 23908 antiandrogen (Anandron®) and estrogen in low doses on hormone‐dependent rat prostatic adenocarcinoma (R3327‐H) were investigated. Tumorbearing Copenhagen rats were treated for 6 weeks with 8 μg Anandron and 1 μg estradiol‐17β every two days. Reduction and counteraction of androgen synthesis and action was established by an observed decline in serum testosterone level and by changes in both histology and weight of androgen target organs. Prostate tumor growth rate… 
View on Wiley
ncbi.nlm.nih.gov
6 Citations

6 Citations

Endocrine mechanisms of suppressive effect of low dose estrogen-antiandrogen treatment on androgen-dependent organs of male rats

Hex administration in low doses, in combination with Fl, could be an alternative method for a complete androgen blockade of the accessory sexual glands in mature intact male rats.

Effect of a nonsteroidal antiandrogen, anandron, on the reproductive system and fertility in male rats.

Evaluation of Win 49,596, a novel steroidal androgen receptor antagonist, in animal models of prostate cancer

A series of experiments were conducted to evaluate the effects of Win 49,596, a novel steroidal androgen receptor antagonist, in animal models of prostate cancer, and decreased the weight of the prostate in tumor‐bearing animals.

Chapter 21. New Horizons in the Treatment of Proliferative Prostatic Disease

Dose and Time-Course Evaluation of a Redox-Based Estradiol-Chemical Delivery System for the Brain. II. Pharmacodynamic Responses

The data demonstrate that the E2-CDS effects on gonadotropins suppression are dose and time dependent and this duration of suppression is consistent with the long half-lives of the E1-Q+ metabolites in the brain.

Consideration of the use of 17β-N,N-diethylcarbamoyl-4-methyl-4-aza-5-α-androstan-3-one (4MA), a 5α-reductase inhibitor, in prostate cancer therapy

4MA decreased tumour growth rate in a dose-dependent manner, which was reflected in a decreased incorporation of BrdUrd in DNA of glandular epithelial cells in the tumour, which has to be interpreted as not being purely due to 5α-reductase inhibition.

References

SHOWING 1-10 OF 22 REFERENCES

Merits and considerations in the use of anti-androgen.

The pure antiandrogen ru 23908 (anandron®), a candidate of choice for the combined antihormonal treatment of prostatic cancer: A review

In intact animals, neutralization of the inhibitory feedback action of endogenous androgens leads to an increased LH and testosterone secretion, which partly overcomes the direct action of the antiandrogen at the level of the prostate and seminal vesicles, which requires prevention of this escape phenomenon through inhibition of LH secretion.

Functionality of estrogen receptor and tamoxifen treatment of R3327 Dunning rat prostate adenocarcinoma.

It was shown that treatment of rats with tamoxifen 5 times/week for 2 to 7 months resulted in marked suppression of tumor growth in 91% of the tumors examined, suggesting that tamoxIFen might be acting directly on the tumor, although an indirect effect cannot be ruled out.

Renewal timing of long‐acting depot luteinizing hormone‐releasing hormone agonist (Zoladex) is critical in the treatment of hormone‐dependent rat prostatic carcinoma (R3327‐H)

The results strongly suggest that careful attention has to be paid to the timing of LHRH depot renewal in prostate cancer treatment, as progressive increasing signs of restoration of normal elements, comparable to non‐treated tumors were observed.

New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens

The present data show that complete withdrawal of androgens by combined hormonal therapy with the LHRH agonist (or castration) and a pure antiandrogen leads to a positive objective response in more than 95% of cases as opposed to 60%‐70% as reported by many groups using the previous partial hormonal therapy.

Comparison of various hormonal therapies for prostatic carcinoma.

Megestrol acetate, the only antiandrogen currently available for use in the United States, has been shown to block androgen from all sources and produces a transient reduction in plasma testosterone to levels somewhat higher than those in castrated men.

A comparison of a powerful luteinizing hormone releasing hormone analogue agonist and estrogen in the treatment of advanced prostatic cancer.

Androgen action blockade does not result in reduction in size but changes histology of the normal human prostate

The effect of androgen blockade on the normal human prostate was studied in 16 healthy volunteers opting for male‐to‐female gender reassignment and histology revealed glandular atrophy and an increase in stromal tissue.

The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors.

The results might indicate that estrone and progesterone treatment stimulated growth of hormone-dependent GR mouse mammary tumors mainly by an increase of growth fraction and cell production rate.

Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas.

It is demonstrated that complete androgen withdrawal consisting of surgical castration in combination with daily treatment with the potent antiandrogen, cyproterone acetate, was no more effective in terms of tumor growth retardation or overall host survival than was partial androgens withdrawal induced by castration alone.